Overview and outlook
Overview of Q2 2020
- Sales rise by 3.7% to € 4.1 billion, EBITDA pre declines by -5.7% to € 1.1 billion
- Healthcare and Performanca Materials more strongly affected by the Covid-19 pandemic than Life Science
- Process Solutions drives growth of Life Science
Outlook for fiscal 2020
- Assumptions regarding the further course of the pandemic largely unchanged
- Group sales between € 16.9 billion and € 17.7 billion expected; lower end of range raised for expected EBITDA pre; forecast is now € 4.45 billion to € 4.85 billion
Despite considerable pandemic-related obstacles in some businesses, overall we did well in the second quarter. In recent months, we again proved the strengths of our diversified business model with three strong, innovation-driven business sectors.
ADDITIONAL INFORMATION
Downloads for the Media
Additional Downloads
- Presentation for Analysts (PDF)
- Financial Statement (XLS)
- Financial Statement (PDF)
- Regional Sector Sales (XLS)
- Summary (PDF)
Annual Reports Archive
Find previous Annual Reports, Corporate Governance Reports & Statements in our archive.
Read more
Q2/2020
Group results
Q2/2020
Business sector results
Related News
View All News-
Press Releases
Second Quarter: Group Remains on Course in a Challenging Environment
Merck KGaA, Darmstadt, Germany, registered the effects of the Covid-19 pandemic in all business sectors in the second quarter. Healthcare and Performance Materials were affected most strongly.
2020/08/06
Upcoming Event
View All EventsOur Q3 2020 results will be published on November 12th, 2020, at 7 a.m. CET. Our conference call for the media will take place at 9:30 a.m. CET, and the conference call for analysts at 2 p.m. CET.
Share Price
Our interactive Share Price Tool provides you with all the information you need. You can retrace our development within the last ten years or follow it in real time – or compare our share price to various indices.
Check Share Price